Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to “Evaluation of nanomedicines: stick to the basics”

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Analysis of studies in clinical trial phases.


  1. 1

    Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    CAS  Article  Google Scholar 

  2. 2

    McNeil, S. Correspondence to the editor. Nat. Rev. Mater. (2016).

  3. 3

    Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232, 255–264 (2016).

    CAS  Article  Google Scholar 

  4. 4

    [No authors listed.] A billion dollar punt. Nat. Biotechnol. 24, 1453 (2006).

  5. 5

    Carroll, J. Merck writes off RNAi, punts Sirna to Alnylam for $175M. FierceBiotech (updated 4 Jul 2016).

  6. 6

    Brunton, L. L., Chabner, B. & Knollmann, B. C. Goodman & Gilman's the Pharmacological Basis of Therapeutics (McGraw-Hill Medical, 2011).

    Google Scholar 

  7. 7

    Sykes, E. A. et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl Acad. Sci. USA 113, E1142–E1151 (2016).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Warren C. W. Chan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Supplementary information S1–S3 (box, figure, table)

Supplementary information (PDF 302 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wilhelm, S., Tavares, A. & Chan, W. Reply to “Evaluation of nanomedicines: stick to the basics”. Nat Rev Mater 1, 16074 (2016).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing